418 related articles for article (PubMed ID: 16908940)
1. Characteristics of asthma resistant to moderate dose inhaled corticosteroid treatment on bronchial hyperresponsiveness.
Fujimoto K; Yamaguchi S; Urushibata K; Hanaoka M; Koizumi T; Honda T; Kubo K
Intern Med; 2006; 45(14):843-9. PubMed ID: 16908940
[TBL] [Abstract][Full Text] [Related]
2. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma.
Ward C; Pais M; Bish R; Reid D; Feltis B; Johns D; Walters EH
Thorax; 2002 Apr; 57(4):309-16. PubMed ID: 11923548
[TBL] [Abstract][Full Text] [Related]
3. Association of symptom control with changes in lung function, bronchial hyperresponsiveness, and exhaled nitric oxide after inhaled corticosteroid treatment in children with asthma.
Park GM; Han HW; Kim JY; Lee E; Cho HJ; Yoon J; Hong SJ; Yang SI; Yang HJ; Yu J
Allergol Int; 2016 Oct; 65(4):439-443. PubMed ID: 27160342
[TBL] [Abstract][Full Text] [Related]
4. Effect of inhaled steroid therapy on exhaled nitric oxide and bronchial responsiveness in children with asthma.
Nishio K; Odajima H; Motomura C; Nakao F; Nishima S
J Asthma; 2006 Dec; 43(10):739-43. PubMed ID: 17169825
[TBL] [Abstract][Full Text] [Related]
5. Prognosis of adult asthma after normalization of bronchial hyperresponsiveness by inhaled corticosteroid therapy.
Tsurikisawa N; Tsuburai T; Oshikata C; Ono E; Saito H; Mitomi H; Akiyama K
J Asthma; 2008 Aug; 45(6):445-51. PubMed ID: 18612895
[TBL] [Abstract][Full Text] [Related]
6. Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients.
Reid DW; Johns DP; Feltis B; Ward C; Walters EH
Respirology; 2003 Dec; 8(4):479-86. PubMed ID: 14629652
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre.
Demarche SF; Schleich FN; Henket MA; Paulus VA; Van Hees TJ; Louis RE
BMJ Open; 2017 Nov; 7(11):e018186. PubMed ID: 29183929
[TBL] [Abstract][Full Text] [Related]
8. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
Koenig SM; Murray JJ; Wolfe J; Andersen L; Yancey S; Prillaman B; Stauffer J; Dorinsky P
Respir Med; 2008 May; 102(5):665-73. PubMed ID: 18328683
[TBL] [Abstract][Full Text] [Related]
9. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma.
van Rensen EL; Straathof KC; Veselic-Charvat MA; Zwinderman AH; Bel EH; Sterk PJ
Thorax; 1999 May; 54(5):403-8. PubMed ID: 10212103
[TBL] [Abstract][Full Text] [Related]
10. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness.
Louis R; Sele J; Henket M; Cataldo D; Bettiol J; Seiden L; Bartsch P
Allergy; 2002 Oct; 57(10):907-12. PubMed ID: 12269936
[TBL] [Abstract][Full Text] [Related]
11. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma.
Shimoda T; Obase Y; Kishikawa R; Iwanaga T
Allergy Asthma Proc; 2016 Jul; 37(4):50-8. PubMed ID: 27401308
[TBL] [Abstract][Full Text] [Related]
12. Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma.
Foresi A; Mastropasqua B; Chetta A; D'Ippolito R; Testi R; Olivieri D; Pelucchi A
Chest; 2005 Jan; 127(1):117-24. PubMed ID: 15653971
[TBL] [Abstract][Full Text] [Related]
13. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
Lee DK; Fardon TC; Bates CE; Haggart K; McFarlane LC; Lipworth BJ
Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
[TBL] [Abstract][Full Text] [Related]
14. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids.
Godon P; Boulet LP; Malo JL; Cartier A; Lemière C
Eur Respir J; 2002 Dec; 20(6):1364-9. PubMed ID: 12503690
[TBL] [Abstract][Full Text] [Related]
15. Mannitol and AMP do not induce bronchoconstriction in eosinophilic bronchitis: further evidence for dissociation between airway inflammation and bronchial hyperresponsiveness.
Singapuri A; McKenna S; Brightling CE; Bradding P
Respirology; 2010 Apr; 15(3):510-5. PubMed ID: 20210888
[TBL] [Abstract][Full Text] [Related]
16. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction.
Luijk B; Kempsford RD; Wright AM; Zanen P; Lammers JW
Eur Respir J; 2004 Apr; 23(4):559-64. PubMed ID: 15083754
[TBL] [Abstract][Full Text] [Related]
17. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma.
Kanniess F; Richter K; Böhme S; Jörres RA; Magnussen H
Eur Respir J; 2002 Oct; 20(4):853-8. PubMed ID: 12412675
[TBL] [Abstract][Full Text] [Related]
18. Comparison of percentage fall in FVC at the provocative concentration of methacholine causing a 20% fall in FEV(1) between patients with asymptomatic bronchial hyperresponsiveness and mild asthma.
Yoo Y; Choung JT; Yu J; Kim DK; Choi SH; Koh YY
Chest; 2007 Jul; 132(1):106-11. PubMed ID: 17505037
[TBL] [Abstract][Full Text] [Related]
19. Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate.
Hoogsteden HC; Verhoeven GT; Lambrecht BN; Prins JB
Clin Exp Allergy; 1999 Jun; 29 Suppl 2():116-24. PubMed ID: 10421834
[TBL] [Abstract][Full Text] [Related]
20. Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment.
Sovijärvi AR; Haahtela T; Ekroos HJ; Lindqvist A; Saarinen A; Poussa T; Laitinen LA
Thorax; 2003 Jun; 58(6):500-4. PubMed ID: 12775860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
